ProShares UltraShort Nasdaq BiotechnologyBIS

ProShares’ UltraShort Nasdaq Biotechnology ETF (BIS) is not for the faint-hearted or the fee-averse. Listed on Nasdaq, the fund’s mandate is explicit: deliver -2× the daily return of the Nasdaq Biotechnology Index before fees and expenses. That means every trading day, BIS resets its exposure to short the basket that includes Amgen, Gilead, Moderna, and a parade of smaller biotechs whose fortunes swing on Phase 3 readouts and FDA decisions. The fund’s fact sheet and regulatory filings confirm this daily reset objective, leaving no room for long-term drift or passive index hugging. (source: Nasdaq, https://www.nasdaq.com/market-activity/etf/bis; SEC EDGAR fund search for BIS, https://www.sec.gov/edgar/search/#/q=BIS)

BIS is one of ProShares’ concentrated and inverse sector ETFs, a family the issuer markets as providing ‘strategic and tactical opportunities to manage risk and enhance returns.’ In practice, BIS turns that promise into a headwind race: the Nasdaq Biotechnology Index can gain or lose 5% in a session, and BIS must adjust its short exposure accordingly by the close. This daily rebalancing is expensive, which is why the fund’s expense ratio sits at 0.95%-a figure that eats directly into any hoped-for relative strength versus simply shorting the index via futures or options. ProShares flags that its ETFs ‘are generally non-diversified and each entails certain risks,’ a gentle way of saying concentration risk and tracking error are baked into each day’s reset. (source: ProShares Browse ETFs by strategy, https://www.proshares.com/our-etfs/find-proshares-etfs/?strategy=Ex-Sector&product=Product+Overview+&search=; ProShares concentrated & Inverse ETFs page, https://www.proshares.com/our-etfs/find-concentrated-and-inverse-etfs)

The fund’s regulatory filings, available on SEC EDGAR, show BIS as a series of ProShares Trust I, a structure that pools assets but keeps each ETF’s risk isolated. The prospectus language consistently warns that the fund’s returns will diverge materially from -2× the index over any period longer than a day, warning investors that ‘imperfect benchmark correlation’ and ‘leverage and market price variance’ can widen gaps in both directions. In other words, BIS is engineered to lose money even when the biotech sector is falling, if the fall isn’t fast enough or deep enough to cover the daily reset costs. (source: SEC EDGAR fund search for BIS, https://www.sec.gov/edgar/search/#/q=BIS)

If you want to see where BIS trades, the Nasdaq ticker page shows intraday price, volume, and bid-ask spreads that reflect the fund’s liquidity profile. The spread can widen during high-volatility biotech sessions, especially around FDA decisions or earnings surprises. The fund’s market depth is not guaranteed; it’s a concentrated product that relies on authorised participants to keep creation and redemption units aligned, and those participants charge for the privilege. (source: Nasdaq BIS page, https://www.nasdaq.com/market-activity/etf/bis)

BIS is not a buy-and-hold instrument. It is a daily tactical tool designed for traders who can stomach the noise, the fee drag, and the tracking error that accompanies a -2× objective. For everyone else, it’s a reminder that the glossiest sector stories often arrive wrapped in the least glamorous fees. (source: ProShares concentrated & Inverse ETFs page, https://www.proshares.com/our-etfs/find-concentrated-and-inverse-etfs/)